TickerGuard
Buy Day today: Neutral (63) Broad market participation · major macro event coming up
RMD

ResMed Inc

Healthcare · Medical Instruments & Supplies

240.50$ +5.9% vs. previous close Closing price · As of: Nov 4, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios RMD
Line item 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Valuation
22.8 25.4 32.4 47.3 43.6 45.0 76.1 39.5 35.9 27.7 27.1 18.7
4.8 4.9 5.4 6.4 6.8 9.5 11.3 8.6 7.6 6.0 7.4 5.0
5.1 5.3 5.7 7.2 8.5 11.2 12.5 9.2 7.8 5.8 6.4 4.3
4.6 5.1 5.6 6.4 7.2 9.7 11.4 8.8 7.9 6.1 7.3 4.9
16.1 17.4 20.3 22.1 26.6 29.0 33.1 26.6 24.6 18.7 19.6 12.9
25.9 18.6 32.4 34.4 46.2 40.2 58.2 158.0 57.6 22.0 22.9 17.3
3.9% 5.4% 3.1% 2.9% 2.2% 2.5% 1.7% 0.6% 1.7% 4.6% 4.4% 5.8%
Margins
60.2% 58.0% 58.1% 58.2% 59.0% 58.1% 57.5% 56.6% 55.8% 56.7% 59.4% 61.1%
24.4% 23.3% 20.6% 23.2% 22.2% 27.4% 28.3% 28.0% 26.8% 28.2% 32.7% 33.8%
21.0% 19.2% 16.6% 13.5% 15.5% 21.0% 14.8% 21.8% 21.3% 21.8% 27.2% 26.9%
18.5% 26.1% 16.6% 18.5% 14.6% 23.5% 19.4% 5.5% 13.2% 27.5% 32.3% 29.2%
Returns
22.2% 20.8% 17.5% 15.3% 19.5% 24.9% 16.4% 23.2% 21.7% 21.0% 23.5% 23.1%
16.2% 10.8% 9.9% 10.3% 9.8% 13.6% 10.0% 15.3% 13.3% 14.9% 17.1% 17.0%
Balance Sheet & Debt
-269 444 472 93 1,124 734 384 523 1,235 494 -511 -781
-0.6 0.8 0.8 0.1 1.6 0.7 0.3 0.4 0.9 0.3 -0.3 -0.4
72.7% 52.0% 56.5% 67.2% 50.4% 54.4% 61.0% 66.0% 61.2% 70.8% 73.0% 73.4%
0.3 0.7 0.7 0.1 0.6 0.5 0.2 0.2 0.4 0.2 0.1 0.1
Per Share
2.47 2.49 2.40 2.19 2.80 4.27 3.24 5.30 6.09 6.92 9.51 10.43
11.77 12.98 14.51 16.25 18.04 20.30 21.83 24.33 28.64 31.75 34.93 38.71
11.12 11.96 13.76 14.30 14.34 17.14 19.70 22.86 28.01 32.97 40.50 45.09
2.18 3.39 2.40 3.01 2.64 4.78 4.23 1.33 3.79 8.72 11.28 11.29

Data as of: November 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?